The use of artificial intelligence (AI) in drug discovery is revolutionizing the pharmaceutical industry. AI-driven drug discovery has the potential to reduce the time and cost of drug development, while also improving the accuracy and efficacy of new treatments. However, the implementation of AI in drug discovery also presents some challenges.
The traditional drug discovery process is a lengthy and expensive process that involves multiple stages of research and development. AI has the potential to streamline this process by automating the analysis of large datasets and providing more accurate predictions of drug efficacy. AI can also help identify new drug targets, predict the safety of potential drugs, and accelerate the drug development process.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.